People: Hi-Tech Pharmacal Co Inc (HITK.O)
HITK.O on Nasdaq
33.70USD
24 May 2013
33.70USD
24 May 2013
Price Change (% chg)
$-0.68 (-1.98%)
$-0.68 (-1.98%)
Prev Close
$34.38
$34.38
Open
$34.13
$34.13
Day's High
$34.40
$34.40
Day's Low
$33.57
$33.57
Volume
50,570
50,570
Avg. Vol
61,289
61,289
52-wk High
$38.17
$38.17
52-wk Low
$27.35
$27.35
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
David Seltzer |
52 | 2004 | Chairman of the Board, President, Chief Executive Officer, Secretary, Treasurer |
Reuben Seltzer |
56 | 2010 | Vice Chairman of the Board |
William Peters |
45 | 2004 | Chief Financial Officer, Vice President |
Gary April |
55 | 1998 | President - Health Care Products Division |
Cameron Durrant |
52 | 2013 | President and Chief Executive Officer of ECR Pharmaceutical Co., Inc. |
Kamel Egbaria |
54 | 2010 | Executive Vice President, Chief Scientific Officer |
Martin Goldwyn |
60 | 1992 | Director |
Yashar Hirshaut |
74 | 1992 | Independent Director |
Anthony Puglisi |
63 | 2005 | Independent Director |
Bruce Simpson |
70 | 2005 | Independent Director |
Jack Van Hulst |
73 | 2008 | Independent Director |
Anne Siebert |
Investor Relations Officer |
Biographies
| Name | Description |
|---|---|
David Seltzer |
Mr. David S. Seltzer is Chairman of the Board, President, Chief Executive Officer, Secretary, Treasurer of Hi-Tech Pharmacal Co Inc. He has been Chairman of the Board since September 2004 and Chief Executive Officer and President of the Company since May 1, 1998 and a Director, Secretary and Treasurer since February 1992. From July 1992 to May 1, 1998 Mr. Seltzer was Executive Vice President - Administration and since July 1992, Vice President – Administration and Chief Operating Officer of the Company since March 1992. Mr. Seltzer received a B.A. in Economics from Queens College in 1984. Mr. Seltzer’s experience brings to the Board an understanding of financial investment, business development, strategic planning, sales and operational management in industry and provides practical guidance, insight and perspective with respect to operations and strategy. |
Reuben Seltzer |
Mr. Reuben Seltzer has been Vice Chairman of the Board of Hi-Tech Pharmacal Co Inc. He has been a Director of the Company since April 1992. Mr. Seltzer is currently serving as Vice Chairman of to the Company in corporate development activities since January 1, 2009. Mr. Seltzer was formerly a Vice Chairman and Director of Neuro-HiTech Pharmaceuticals, Inc., a drug development company engaged in the development and commercialization of products in the specialty pharmaceutical area. Mr. Seltzer is no longer affiliated with this company as an Officer or Director. Mr. Seltzer had been president of R.M. Realty Services Inc., a real estate investment and consulting company from May 1988 to September 1992. From May 1983 to May 1988 Mr. Seltzer was a vice president and attorney with Merrill Lynch Hubbard Inc., a real estate investment subsidiary of Merrill Lynch and Company. Mr. Seltzer received a B.A. in Economics from Queens College in 1978, a Juris Doctor from the Benjamin N. Cardozo School of Law in 1981 and a L.L.M. from the New York University School of Law in 1987. |
William Peters |
Mr. William J. Peters is Chief Financial Officer, Vice President of Hi-Tech Pharmacal Co Inc., since May 2004. From September 2003 to May 2004 he was Vice President of Corporate Development. From 1998 to 2001 Mr. Peters was Manager of Corporate Financial Analysis and Pharmaceutical Economics at Merck & Co., Inc. (“Merck”). From 2001 to September 2003, he was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck. During his seven year career at Merck, he also served as Manager of Treasury Planning and Analysis. He began his career in General Electric’s Financial Management Program at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from Wharton School of Business, University of Pennsylvania in 1996 and a B.S. in Business Administration from Bucknell University. |
Gary April |
Mr. Gary M. April is President - Health Care Products Division of Hi-Tech Pharmacal Co Inc., since May 1998. He was Divisional Vice President of Sales since January 1993. |
Cameron Durrant |
Dr. Cameron Durrant is appointed as the President and Chief Executive Officer of ECR Pharmaceutical Co., Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. He has been a consultant for ECR for the past six months and worked in the pharmaceutical industry for 22 years, and in medical practice for 8 years prior. He has been CEO or interim CEO for four venture-backed companies and CFO of a public company. He has been a senior executive at Johnson and Johnson, Pharmacia Corporation (until its acquisition by Pfizer), GSK and Merck. He has served as the founding investor, Chairman, CEO and CFO of publicly-traded PediatRx, Executive Chairman of publicly-traded Anavex, CEO of PediaMed Pharmaceuticals, a founding director of Bexion Pharmaceuticals, a board member of Topaz Pharmaceuticals (acquired by sanofi-aventis), and a board member of Alcyone Life Sciences. Dr. Durrant has been an advisor to Microsoft Corporation, Prism Pharmaceuticals (acquired by Baxter), Pilgrim Software (acquired by a private equity group), Aprecia Pharmaceuticals and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children’s Hospital and assisted numerous private equity groups in their diligence efforts. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxford, UK. |
Kamel Egbaria |
Dr. Kamel Egbaria, Ph.D., is Executive Vice President, Chief Scientific Officer of Hi-Tech Pharmacal Co Inc., since April 2010. From 2003 to 2009, Mr. Egbaria was the Chief Scientific Officer and Vice President of Research and Development for Qualitest Pharmaceuticals, Inc. |
Martin Goldwyn |
Mr. Martin M. Goldwyn serves as Director of Hi-Tech Pharmacal Co Inc., since May 1992. Mr. Goldwyn is a member in the law firm of Tashlik, Kreutzer, Goldwyn & Crandell P.C. Mr. Goldwyn received a B.A. in finance from New York University in 1974 and a Juris Doctor from New York Law School in 1977. |
Yashar Hirshaut |
Dr. Yashar Hirshaut, M.D., is Independent Director of Hi-Tech Pharmacal Co Inc., since September 1992. Dr. Hirshaut is a practicing medical oncologist and is currently an Associate Clinical Professor of Medicine at Cornell University Medical College. Since July 1986, he has been a Research Professor of Biology at Yeshiva University. In addition, he has served as editor-in-chief of the Professional Journal of Cancer Investigation since July 1981. Dr. Hirshaut received a B.A. from Yeshiva University in 1959 and his medical degree from Albert Einstein College of Medicine in 1963. |
Anthony Puglisi |
Mr. Anthony J. Puglisi is Independent Director of Hi-Tech Pharmacal Co Inc., since September 21, 2005. Mr. Puglisi is Chief Financial Officer of the IMI Merchandising group of IMI plc, a publicly traded British company. Mr. Puglisi was Vice President and Chief Financial Officer of Sbarro, Inc., an owner, operator and franchisor of quick-service restaurants, from February 2004 to April 2009. Prior to joining Sbarro, Mr. Puglisi was the Vice President and Chief Financial Officer of Langer, Inc., a provider of products used to treat muscle-skeletal disorders, from April 2002 to February 2004. Mr. Puglisi was Senior Vice President and Chief Financial Officer of Netrex Corporation from September 2000 to October 2001 and Executive Vice President and Chief Financial Officer of Olsten Corporation, a provider of staffing and home health care services from 1993 to March 2000. Mr. Puglisi has been a certified public accountant in New York for over twenty-five years. He earned a B.B.A. in Accounting from Bernard Baruch College. Mr. Puglisi is a director of CPNA International. |
Bruce Simpson |
Mr. Bruce W. Simpson is Independent Director of Hi-Tech Pharmacal Co Inc., since September 9, 2005. Mr. Simpson is President and CEO of B.W. Simpson & Associates, a consulting company that works with small emerging pharmaceuticals companies in the areas of marketing, business development and strategic planning. Prior to founding his own healthcare-consulting firm in 1998, from July 1998 to August 1999, Mr. Simpson was President of Genpharm, Inc., located in Ontario, Canada, a division of E. Merck. From 1992 to July 1998, he served as President and CEO of Medeva Pharmaceuticals in Rochester, New York. He has been affiliated with American Academy of Allergy and is a former Director of Draxis Health Inc., Bradley Pharmaceuticals and Adams Laboratories. Mr. Simpson holds a B.S. in Marketing from Fairleigh Dickinson University, an M.B.A. in Marketing from the University of Hartford, and has done post-graduate work in healthcare marketing at UCLA. Prior to entering the pharmaceutical field, Mr. Simpson served as a Captain in the United States Marine Corps. |
Jack Van Hulst |
Mr. Jack Van Hulst is Independent Director of Hi-Tech Pharmacal Co Inc. He has been a senior executive with 42 years of domestic and global experience in many sectors of the pharmaceutical industry. From 1999 to 2005 he was Executive Vice President of MOVA Pharmaceutical Corporation, a contract manufacturer in Puerto Rico with three manufacturing sites and approximately 1,700 employees. MOVA merged with the publicly held Canadian contract manufacturer Patheon, which is the worldwide pharmaceutical contract manufacturer. From 1997 to 1998, he was a consultant responsible for special project implementation related to Women’s Healthcare at Population Council. From 1993 to 1996 he was part owner, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc., a manufacturer and marketer of generic liquid prescriptions and OTC pharmaceuticals prior to its sale to William Blair Capital Partners. From 1991 to 1993 he was part owner, President and Chief Executive Officer of Pennex Products, Inc., a manufacturer and marketer of OTC drugs prior to its sale to Rexall-Sundown. He is a Board Member of The International Center, New York, New York; Senesco Technologies, Inc., New Brunswick, New Jersey (AMEX:NST); and Napopharma (LSE:NAPU). He received a Law Degree from the University of Utrecht, The Netherlands. |
Anne Siebert |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
David Seltzer |
878,000 |
Reuben Seltzer |
812,000 |
William Peters |
549,000 |
Gary April |
319,000 |
Cameron Durrant |
-- |
Kamel Egbaria |
1,216,000 |
Martin Goldwyn |
-- |
Yashar Hirshaut |
-- |
Anthony Puglisi |
-- |
Bruce Simpson |
-- |
Jack Van Hulst |
-- |
Anne Siebert |
-- |
As Of 29 Apr 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
David Seltzer |
987,500 | 19,083,000 |
Reuben Seltzer |
67,500 | 2,032,000 |
William Peters |
194,267 | 1,997,000 |
Gary April |
112,968 | 1,459,000 |
Cameron Durrant |
0 | 0 |
Kamel Egbaria |
0 | 0 |
Martin Goldwyn |
0 | 0 |
Yashar Hirshaut |
0 | 0 |
Anthony Puglisi |
0 | 0 |
Bruce Simpson |
0 | 0 |
Jack Van Hulst |
0 | 0 |
Anne Siebert |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PETERS WILLIAM J |
36 | $10.68 |
PETERS WILLIAM J |
36 | $38.00 |
PETERS WILLIAM J |
4,603 | $10.68 |
PETERS WILLIAM J |
4,603 | $38.00 |
PETERS WILLIAM J |
7,861 | $38.00 |
PETERS WILLIAM J |
1,611 | $10.68 |
PETERS WILLIAM J |
6,250 | $10.68 |
SELTZER DAVID S |
112,500 | $11.56 |
SELTZER DAVID S |
35,092 | $37.06 |
SELTZER DAVID S |
350 | $0.00 |
SELTZER DAVID S |
1,050 | $0.00 |
APRIL GARY M |
1,875 | $19.59 |
APRIL GARY M |
1,876 | $22.25 |
APRIL GARY M |
1,875 | $5.83 |
APRIL GARY M |
5,626 | $35.44 |
GOLDWYN MARTIN M |
2,832 | $8.31 |
GOLDWYN MARTIN M |
2,832 | $0.00 |
HIRSHAUT YASHAR |
11,250 | $8.31 |
SELTZER REUBEN |
6,800 | $32.56 |
SELTZER DAVID S |
29,441 | $32.60 |
GOLDWYN MARTIN M |
421 | $19.59 |
GOLDWYN MARTIN M |
421 | $0.00 |
VAN HULST JACK |
3,000 | $5.83 |
VAN HULST JACK |
3,000 | $32.75 |
SELTZER DAVID S |
20,559 | $32.97 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
